Amgen
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
Countdown
192days
Phase 3 readout · Jan 15, 2027
What's at stake
Phase 3 trial results for Ocrelizumab (US) in Relapsing-remitting Multiple Sclerosis (RRMS) are due Jan 15, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06700343: Phase 3 trial, sponsor Amgen, drug Ocrelizumab (US). Primary completion date 2027-01-15 (estimated).”